Pulmonary Vascular Reactivity and Prognosis in Patients With Chronic Thromboembolic Pulmonary Hypertension A Pilot Study

被引:55
作者
Skoro-Sajer, Nika [1 ]
Hack, Niklas [2 ]
Sadushi-Kolici, Roela [1 ]
Bonderman, Diana [1 ]
Jakowitsch, Johannes [1 ]
Klepetko, Walter [3 ]
Hoda, Mir Ali Reza [3 ]
Kneussl, Meinhard P. [4 ]
Fedullo, Peter [5 ]
Lang, Irene M. [1 ]
机构
[1] Med Univ Vienna, Vienna Gen Hosp, Dept Internal Med 2, Div Cardiol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Vienna Gen Hosp, Sect Med Stat, A-1090 Vienna, Austria
[3] Med Univ Vienna, Vienna Gen Hosp, Dept Cardiothorac Surg, A-1090 Vienna, Austria
[4] Wilhelminenspital Stadt Wien, Vienna, Austria
[5] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA
关键词
pulmonary heart disease; hypertension; pulmonary; thrombosis; endarterectomy; survival; INHALED NITRIC-OXIDE; ACUTE HEMODYNAMIC-RESPONSES; INTRAVENOUS EPOPROSTENOL; BOSENTAN THERAPY; VASODILATION; THROMBOENDARTERECTOMY; VASOREACTIVITY; PROSTACYCLIN; EXPERIENCE; PERFUSION;
D O I
10.1161/CIRCULATIONAHA.108.794610
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Surgical pulmonary endarterectomy is the preferred treatment for chronic thromboembolic pulmonary hypertension. Persistent pulmonary hypertension after pulmonary endarterectomy has been recognized as a major determinant of poor outcome. We tested whether acute vasoreactivity identifies chronic thromboembolic pulmonary hypertension patients prone to develop persistent/recurrent pulmonary hypertension after pulmonary endarterectomy and whether the degree of acute vasoreactivity affects survival or freedom from lung transplantation. Methods and Results-Right-sided heart catheterization at baseline and after inhalation of 40 ppm nitric oxide for 20 minutes was performed in 103 patients (56.3 +/- 15.3 years old, 53 women). Reductions in mean pulmonary arterial ressure (Delta mPAP; -8.8 +/- 12.6%; P<0.0001) and pulmonary vascular resistance (-16.1 +/- 18.1%; P<0.0001) and an increase in mixed venous saturation during inhaled nitric oxide (9.1 +/- 11.6%; P<0.0001) were observed. Sixty-two patients underwent pulmonary endarterectomy after a median of 49 days (25th and 75th percentiles: 24 and 123 days). Operated patients were followed up for a median of 70.9 months (25th and 75th percentiles: 14 and 97 months). Change in mPAP during inhaled NO was identified as a predictor of persistent/recurrent pulmonary hypertension after pulmonary endarterectomy. Patients experiencing a reduction in mPAP > 10.4% with nitric oxide inhalation had a better postoperative outcome. A significant correlation was found between Delta mPAP and immediate postoperative pulmonary vascular resistance (r = 0.5, P < 0.0001). Conclusions-A total of 80 (77.7%) of 103 patients demonstrated acute pulmonary vascular reactivity of some degree. A decrease in mPAP >10.4% under inhaled nitric oxide is a predictor of long-term survival and freedom from lung transplantation in adult patients with chronic thromboembolic pulmonary hypertension who are undergoing pulmonary endarterectomy. (Circulation. 2009;119:298-305.)
引用
收藏
页码:298 / 305
页数:8
相关论文
共 43 条
[1]   Long-term outcome after pulmonary thromboendarterectomy [J].
Archibald, CJ ;
Auger, WR ;
Fedullo, PF ;
Channick, RN ;
Kerr, KM ;
Jamieson, SW ;
Kapelanski, DP ;
Watt, CN ;
Moser, KM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (02) :523-528
[2]   Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing [J].
Atz, AM ;
Adatia, I ;
Lock, JE ;
Wessel, DL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) :813-819
[3]  
Azarian R, 1997, J NUCL MED, V38, P980
[4]   Diagnosis and differential assessment of pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
Torbicki, A ;
Sitbon, O ;
Krowka, MJ ;
Olschewski, H ;
Gaine, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :40S-47S
[5]   Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism [J].
Becattini, Cecilia ;
Agnelli, Giancarlo ;
Pesavento, Raffaele ;
Silingardi, Mauro ;
Poggio, Renzo ;
Taliani, Maria Rita ;
Ageno, Walter .
CHEST, 2006, 130 (01) :172-175
[6]  
Bonderman D, 2005, CHEST, V128, P2599, DOI 10.1378/chest.128.4.2599
[7]   Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension [J].
Bresser, P ;
Fedullo, PF ;
Auger, WR ;
Channick, RN ;
Robbins, IM ;
Kerr, KM ;
Jamieson, SW ;
Rubin, LJ .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) :595-600
[8]  
Bresser Paul, 2006, Proc Am Thorac Soc, V3, P594, DOI 10.1513/pats.200605-115LR
[9]   Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension [J].
Cabrol, Segolene ;
Souza, Rogerio ;
Jais, Xavier ;
Fadel, Elie ;
Ali, Ratiba Haddad Si ;
Humbert, Marc ;
Dartevelle, Philippe ;
Simonneau, Gerald ;
Sitbon, Olivier .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (04) :357-362
[10]   Long-term outcome after pulmonary endarterectomy [J].
Corsico, Angelo G. ;
D'Armini, Andrea M. ;
Cerveri, Isa ;
Klersy, Catherine ;
Ansaldo, Elena ;
Niniano, Rosanna ;
Gatto, Elena ;
Monterosso, Cristian ;
Morsolini, Marco ;
Nicolardi, Salvatore ;
Tramontin, Corrado ;
Pozzi, Ernesto ;
Vigano, Mario .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (04) :419-424